Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
By mid-September, the Centers for Disease Control and Prevention reported the Omicron subvariant KP.3.1.1 accounted for most COVID-19 cases. KP.3.1.1 is a member of a group of variants nicknamed ...
Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...